Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that PP2A regulates Girdin dephosphorylation and highlight the critical role of this pathway in breast cancer metastasis.
|
30935690 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
|
29229993 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data point to CIP2A and PP2A as novel therapeutic targets for AI-resistant breast cancer.
|
29805747 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the clinical significance of p-PP2A and phospho-AKT (p-AKT) expression in 672 patients with breast cancer during a 15-year follow-up.
|
28603063 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the role of the tumor suppressor PP2A in modulating ER and AR signaling in breast cancer, the molecular mechanisms involved, and its biological and therapeutic impact.
|
28916342 |
2017 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression of a breast cancer-associated PP2A-A mutant, PP2A-Aα-E64G, which inhibits binding of regulatory subunits to the PP2A core, induced a similar hyper-proliferative phenotype.
|
28744751 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, the present study provides further evidence that PP2A represents a therapeutic target for AI-resistant breast cancer.
|
29344249 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This work suggests that approaches to target the RACK1/PP2A complex are a viable option to regulate PP2A activity and identifies a novel potential therapeutic target in the treatment of breast cancer.
|
27600565 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that Notch-1-activating PI3K/AKT/NF-κB pathway is PP2A dependent; PP2A may be a potential therapeutic target in breast cancer.
|
26945854 |
2016 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because of the ubiquitous expression and tumor suppressor activity of PP2A in cells, as well as the critical role of c-MYC in human cancer, we propose that activation of PP2A (here accomplished through antagonizing endogenous inhibitors) could be a novel antitumor strategy to posttranslationally target c-MYC in breast cancer.
|
24927563 |
2014 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cantharidin and norcantharidin are potent protein phosphatase 2A (PP2A) inhibitors that exhibit in vitro and in vivo antitumor activity against several types of cancer, including breast cancer.
|
23835679 |
2013 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examine here the various functions of NO and PP2A in breast cancer and propose a novel mechanism by which activation of PP2A antagonizes NO signaling that promotes ER(-) breast cancer.
|
21893353 |
2011 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Given the tumor suppressor activities of PP2A, here we evaluate whether this genetic variant associates with the age of diagnosis and recurrence of breast cancer in women.
|
20669227 |
2011 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding the role of PP2A in HER2/neu positive cells might thus provide insight into new targets for breast cancer therapy.
|
20558158 |
2010 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The authors evaluated genetic variation of PP2A holoenzyme subunits for their potential contribution to breast cancer risk.
|
19890961 |
2010 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HUNK reconstitution in basal breast cancer cell lines prevented protein phosphatase 2-A (PP2A), a phosphatase putatively acting on CFL-1, from binding to CFL-1.
|
20133759 |
2010 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
|
16276521 |
2006 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the frequency of alterations is low, the inclusion of both isoforms of subunit A in the genes mutated in human cancer and the addition of breast cancer to the list of neoplasms in which PPP2R1B is altered, strengthen the potential role of PP2A in human tumorogenesis.
|
10713707 |
2000 |